Roche AG

Roche AG
Roche AG  
Discipline: Medicine/Pharmacology
Health - May 16
Phase I/II study of entrectinib, an investigational medicine, showed responses in all paediatric tumour types harbouring neurotrophic tyrosine receptor kinase (NTRK), ROS1 or anaplastic lymphoma kinase (ALK) fusions, including those in the central nervous system Data featured in the ASCO presscast on Wednesday, 15 May, and will be presented at t
Pharmacology - May 16

Fixed 12-month treatment with Venclexta plus Gazyva significantly reduced risk of disease progression or death by 67% compared to a current standard-of-care Approval for expanded use of Venclexta offers more adults with chronic lymphocytic leukaemia a new treatment option - Roche today announced

Health - May 14

Parties elect to refile Premerger Notification and Report Forms on or about 23 May 2019 to provide the government with additional time to complete its current review Roche and Spark Therapeutics, Inc.

Health - May 7

In the dose-finding Part 1 of FIREFISH, infants with Type 1 spinal muscular atrophy survive and achieve key milestones beyond those expected in the natural history of the disease New data from the dose-finding Part 1 of SUNFISH reinforce risdiplam as a promising investigational therapy for people

Pharmacology - Apr 29

Risdiplam data from Part 1 of pivotal FIREFISH study show infants with Type 1 spinal muscular atrophy achieve key motor milestones and improved survival after one year of treatment New analyses in relapsing and primary progressive multiple sclerosis suggest that higher OCREVUS (ocrelizumab) expos

Health - Apr 3

Roche and Spark Therapeutics, Inc. (NASDAQ: ONCE) (“Spark”) today announced that Roche has withdrawn its Premerger Notification and Report Form under the Hart-Scott-Rodino Act (the “HSR Act”) in connection with Roche's pending acquisition of Spark.

Health - May 14

New tests on cobas 6800/8800 systems provide clinicians information to help speed treatment and reduce the spread of infection Rising challenge of drug resistance compounds the tuberculosis global health crisis Mycobacteria test menu allows detection of tuberculosis, drug resistant tuberculosis a

Pharmacology - May 10

Study results across 17 medicines reflect our commitment to personalised care with advances in targeted therapies, immunotherapy, and diagnostics, data and analytics New pivotal data on fixed-duration combination of Venclexta/Venclyxto plus Gazyva/Gazyvaro in previously untreated chronic lymphocy

Pharmacology - May 6

The approval is based on data showing Kadcyla cut the risk of disease recurring by half compared to Herceptin in the adjuvant setting for specific patients with HER2-positive early breast cancer The application was approved in just over 12 weeks under the US FDA's Real-Time Oncology Review pilot

Health - Apr 23

Nearly 2.1 million new cases of breast cancer are diagnosed worldwide each year, and more than 620,000 people will die from the disease. 1 About 15 to 20 percent of women diagnosed with breast cancer are HER2 positive.

Pharmacology - Apr 1

Data from Phase Ib study to be presented at American Association for Cancer Research (AACR) 2019 annual congress 73% overall response rate (ORR) irrespective of PD-L1 status or PI3KCA/AKT1/PTEN alteration status Roche will today present the initial results from a Phase Ib study evaluating the eff

website preview


Medicine and Life Sciences